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Abstract
The goal of this study was to analyze the local and systemic cytokine responses in patients with
Community-acquired pneumonia (CAP) and to develop a model to integrate multiple cytokine
data in order to investigate the relationships of different cytokine patterns with measures of CAP
outcomes and severity. Forty hospitalized patients enrolled through the Community Acquired
Pneumonia Inflammatory Study Group (CAPISG) were included. Based on the ranked distribu-
tion of the levels of eight different pro-inflammatory cytokines (IL-1β , IL-6, IL-8, IL-12p40, IL-17A,
IFNγ, TNFα and CXCL10) in both plasma and sputum on the day of hospital admission, "pro-
inflammatory cytokine scores (PICS)" were calculated for each patient. PICS in plasma were
divided by those in sputum in order to calculate a pro-inflammatory cytokine ratio (PICR). Com-
parison of PCIR values for patients grouped by TCS (≤ and >3 days) or by TSI group (classes
I-III and IV-V) indicated statistically significant differences. Patients in the TCS>3d group had sig-
nificantly higher PICR compared to the TCS≤3d group (p=0.009) and patients in PSI class IV-V
had higher PICR values compared to those in PSI classes I-III (p=0.042). ROC analysis showed
that PICR values have a good accuracy at separating patients into either of the TCS groups, sug-
gesting the potential use as predictive tools, identifying patients at risk to have a delayed TCS or
a more severe disease.
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1 Introduction
Despite the availability and use of antimicrobial therapy,
community-acquired pneumonia (CAP) remains one of the major
causes of infectious disease-related death in the world1,2. In CAP,
a local immune response to the invading microorganisms induces
the recruitment and activation of leukocytes to the lungs3,4. Even
in the presence of antimicrobial therapy, this response plays a key
role in determining whether or not the offending microorganisms
escape control and further spread beyond the lungs, eliciting a
vigorous systemic inflammatory response5,6.
While the initial inflammatory response has a protective role, ex-
cessive or uncontrolled inflammation may result in deleterious
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consequences for the host6–8. In fact, an association between
an exaggerated systemic inflammatory response (i.e., "cytokine
storm") with poor clinical outcomes has been established by sev-
eral investigators6,9,10 and it is generally agreed that failure to
control excessive inflammation may lead to organ damage and a
higher mortality risk6,9–12. The potentially deleterious role of dis-
proportionate inflammation has prompted several studies to ex-
plore the therapeutic use of immunomodulatory corticosteroids in
CAP patients. Unfortunately, results have been inconsistent and
their real efficacy so far remains controversial13–17. While the
reasons for the discrepancies are not clear, it has been suggested
that although only a subset of CAP patients may actually benefit
from corticosteroid use (those with the most severe inflamma-
tion), most studies have enrolled patients without consideration
of their inflammatory status18.
Based on previous studies19 we have hypothesized that patients
who are able to mount strong local inflammatory responses might
be able to have better clinical outcomes. However, while most
studies in CAP patients have focused on the association between
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Fig. 1 Plasma cytokine distributions in CAP patient groups relative to the TCS. Blood samples from patients with TCS≤3d (n=26) or TCS>3d (n=16)
were obtained shortly after admission to the hospital and assayed for the indicated cytokines and chemokines using a bead-based multiplex assay as
indicated in Materials and Methods. Box plots depict the 25-75% interquartile range and the horizontal bar depicts the median. Due to non-normal
distribution of cytokine scores, groups were compared using the Wilcoxon-Mann-Whitney test. *p < 0.05.
disease severity or clinical outcomes and the systemic inflamma-
tory response (measured in serum or plasma), data on associa-
tions with the local inflammatory response, such as measured in
bronchoalveolar lavage (BAL) or sputum, are limited. Thus, the
aims of this study were to investigate the association of both, local
and systemic cytokine response patterns, with the time to clinical
stability (TCS) and to explore potential means to integrate the
overall cytokine response (plasma and sputum) in the evaluation
of CAP patients.
2 Materials and Methods
This was a secondary analysis of data previously collected from
the Community Acquired Pneumonia Inflammatory Study Group
(CAPISG). The design of our study has been previously de-
scribed19. Briefly, this study included 40 patients with CAP
hospitalized at the University of Louisville Hospital or the
Louisville’s Veteran Administration Hospital from 01/04/2011 to
01/08/2012. The study was approved by both the University
of Louisville Human Subjects Program Protection Office and the
Robley Rex Veterans Affairs Medical Center Institutional Review
Boards (Approvals #: 07.0182 and 0009, respectively). The de-
mographic and clinical data of the patient population in this study
has already been reported19.
2.1 Criteria for CAP
CAP was defined as evidence of a new pulmonary infiltrate at
chest radiograph associated with at least one of the following:
1) new or increased cough; 2) fever or hypothermia; and 3)
leukocytosis, left shift, or leukopenia. Pneumonia was defined
as community-acquired if a patient had no history of hospitaliza-
tion during the 2 weeks prior to admission. The inclusion and
exclusion criteria and full case report forms for this study can be
found at the Community Acquired Pneumonia Organization study
site at www.caposite.com.
2.2 Microbiologic Analysis
Testing of sputum samples and blood cultures; serology for res-
piratory viruses and atypical organisms as well as urinary anti-
gens for Legionella spp. and Streptococcus pneumoniae were
performed according to standard clinical practice. The identifica-
tion of microorganisms and susceptibility testing were performed
according to standard methods20. Cases in which no specific eti-
ologic agent was isolated or identified were classified as CAP of
unknown etiology.
2.3 Severity of Disease and Time to Clinical Stability
The Pneumonia Severity Index (PSI) was used to define CAP
severity21. Hospitalized patients were considered to have severe
CAP if their PSI was Risk Class IV or V (91 points or higher). Pa-
tients with a PSI Risk Class of I-III (<91 points) were defined as
having non-severe CAP. Accordingly, 21 patients were classified
as having severe and 19 non-severe CAP. The time to clinical sta-
bility (TCS) was defined based on the American Thoracic Society
(ATS)/Infectious Diseases Society of America (IDSA) 2007 guide-
lines as improved clinical signs (cough and shortness of breath),
lack of fever for at least 8 hours, improving leukocytosis (de-
creased at least 10% from the previous day), and tolerating oral
intake22. For this study, patients were divided into two groups
based on a TCS equal or less than 3 days (TCS≤3d) and a TCS
greater than three days (TCS>3d). Accordingly, 24 patients were
classified as having a TCS≤3d and 16 patients a TCS>3d.
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Fig. 2 Sputum cytokine distributions profiles in CAP patient groups relative to the TCS. Sputum samples from patients with TCS≤3d (n=8) or TCS>3d
(n=7) were obtained shortly after admission to the hospital and processed and assayed for the indicated cytokines and chemokines using a
bead-based multiplex assay as indicated in Materials and Methods. Box plots depict the 25-75% interquartile range and the horizontal bar depicts the
median. Due to non-normal distribution of cytokine scores, groups were compared using the Wilcoxon-Mann-Whitney test.
2.4 Samples
Plasma samples: Blood samples were obtained on the day of ad-
mission at the hospital. Venous blood was collected using sodium
citrate Vacutainer tubes. Following centrifugation at 300 x g for
10 min, the plasma was separated by aspiration, aliquoted and
stored frozen at -80◦C until assayed.
Sputum samples: Sputum samples were collected from a total of
15 CAP patients (7 with non-severe, 8 with severe CAP) on the
day of admission to the hospital. Sputum samples were processed
following the method described by Pizzichini et al23. The cell-free
supernatants were aliquoted and stored frozen at -80◦C until used
for the measurement of cytokine levels.
2.5 Cytokine measurements
The concentrations of ten different cytokines and chemokines
in plasma and sputum samples were determined using Milli-
plex MAP High Sensitivity Human Cytokine Magnetic bead kits
(HSCYTMAG-60SK, EMD Millipore, Billerica, MA) according to
the manufacturer’s instructions. The panel included eight im-
portant pro-inflammatory cytokines and chemokines: interleukin
(IL)-1β , IL-6, CXCL8 (IL-8), IL-12p40, IL-17A, interferon (IFN)γ,
tumor necrosis factor (TNF)α and CXCL10 (IP-10); and two main
anti-inflammatory cytokines: IL-1 receptor antagonist (IL-1ra)
and IL-10.
2.6 Statistics
Statistical analysis and graphs were performed using GraphPad
Prism 5.0 (GraphPad Software, La Jolla, CA). Data distribution
was analyzed using the D’Agostino and Pearson omnibus normal-
ity test. Due to a non-normal distribution of cytokine data, sta-
tistical comparisons between the groups were performed using
the Wilcoxon-Mann-Whitney test. Unpaired t-tests were used to
compare normally-distributed data. GraphPad was used to con-
struct ROC curves. The Youden’s Index (J) was calculated as J =
(specificity + sensitivity)-1. p-values of ≤0.05 were considered
statistically significant.
3 Results
3.1 Cytokine Patterns in Plasma and Sputum and Associa-
tion with the TCS
In order to associate cytokine patterns with time to clinical stabil-
ity (TCS), we compared the plasma and sputum cytokine levels
in patients divided in two groups based on their TCS (≤ and >
3 days) as indicated in the Methods section. Figure 1 shows the
distribution of plasma concentration values for the ten different
cytokines measured. Despite the overlap in values between the
two groups, patients in the TCS>3d group had statistically signif-
icantly higher plasma levels (p<0.05) of the pro-inflammatory cy-
tokines, IL-6 and IL-8, as well as the anti-inflammatory cytokine,
IL-10. There were no statistically significant differences between
the two groups for the other cytokines. In the case of cytokine
concentrations in sputum (Figure 2), there was a tendency for
higher cytokine levels in the TCS≤3d group in the case of the
pro-inflammatory cytokines, particularly IL-1β (p=0.11), TNFα
(p=0.06) and IFNγ (p=0.08), but no statistically significant dif-
ferences were recorded.
3.2 Pro-Inflammatory Cytokine Ratio (PICR)
In order to integrate systemic and local inflammatory cytokine
response profiles in CAP patients, a ratio based on the relative
levels of the eight pro-inflammatory cytokines and chemokines
ULJRI Vol 1,(3) 2017 13–20 | 15
Table 1 Distribution of ranked cytokine values in plasma and sputum
Cytokine 25% percentile Median 75% percentile
Plasma
IL-1β 0.1 0.1 0.1
IL-1Ra 0.4 2.1 37.3
IL-6 2.7 10.2 40.1
IL-8 6.8 14.0 33.7
IL-10 0.9 7.3 17.3
IL-12p70 3.2 3.2 14.0
IL-17 0.5 1.3 8.7
IFNγ 0.2 2.9 9.9
TNFα 5.8 11.5 22.1
CXCL10 (IP-10) 358.8 992.2 2,158.0
Sputum
IL-1 66.2 289.0 1,738.0
IL-1Ra 16,966.0 26,784.0 124,294.0
IL-6 25.8 163.6 1,212.0
IL-8 4,040.0 29,098.0 91,269.0
IL-10 6.0 6.0 81.9
IL-12p70 2.8 2.8 172.8
IL-17 8.6 12.2 36.1
IFNγ 5.2 9.1 28.3
TNFα 20.7 257.5 1,415.0
CXCL10 190.4 439.7 4,848.0
All cytokine values are expressed in pg/mL. Plasma samples (n=40); Sputum samples (n=15)
Table 2 Characteristics of CAP patients with both Plasma and Sputum Cytokine Data
Patient Age/Sex PSI Class TCS Etiologic Agent Plasma/Sputum PICR
(Days) (PICS)
TCS<3d Group
1 78/M III 2 Streptococcus pneumoniae 16 / 18 0.88
2 51/F II 2 Streptococcus pneumoniae 19 / 21 0.90
3 65/M III 2 Streptococcus pneumoniae 11 / 19 0.57
4 58/M II 2 Haemophilus influenzae 30 / 24 1.25
5 54/F IV 2 Influenza A H3 22 / 23 0.95
6 63/M III 2 None identified 14 / 25 0.56
7 53/F II 2 None identified 13 / 17 0.76
8 49/M IV 1 None identified 14 / 19 0.73
TCS>3d Group
9 40/M II 7 Pseudomonas aeruginosa 25 / 26 0.96
10 62/M V >6* MRSA 21 / 19 1.10
11 57/F IV 6 Acinetobacter baumannii 17 / 21 0.80
12 72/F IV 4 None identified 23 / 14 1.64
13 78/M V 3 None identified 20 / 13 1.53
14 85/M V 7 None identified 17 / 13 1.30
15 59/M IV >3* None identified 21 / 12 1.75
*patient died during hospital stay
measured in plasma vs. sputum was calculated. As a first step,
the distributions of the concentration levels for all cytokines mea-
sured in plasma (n=40) and sputum samples (n=15) were ana-
lyzed and ranked in quartiles. The cytokine values (in pg/mL) for
the 25% percentile, median and 75% percentile for each of the
measured cytokines in plasma and sputum are shown in Table 1
and Supplementary Figs. 1-2). Next, for the 15 patients having
both plasma and sputum data available, each of the eight pro-
inflammatory cytokines was given a score of 1 through 4, accord-
ing to the quartile it belonged (e.g., 1 for <25%, 2 for 25-50%, 3
for 50-75% and 4 for >75%). Then, the eight cytokine scores in
plasma and sputum were added and the total defined as the "Pro-
inflammatory cytokine score (PICS)" for the corresponding fluid.
Finally, the PICS in plasma was divided by that in the sputum
to obtain the Pro-inflammatory cytokine ratio (PICR). The values
thus calculated for each of the 15 patients are shown in Table 2,
along with their relevant clinical information. The TCS≤3d group
(n=8) included five patients in PSI risk classes I-III and three in
PSI risk classes IV-V; whereas the TCS>3d group (n=7) included
two patients in PSI risk classes I-III and five in PSI risk classes
IV-V.
3.3 Integration of Cytokine Response Profiles
In order to compare the combined cytokine response patterns in
plasma and sputum among the patients and to investigate their
association with measures of CAP outcomes (TCS) and severity
(PSI), we developed an initial model based on a score, the PICR,
calculated based on the ranked cytokine scores in plasma divided
by sputum. The calculated PICR values for each patient are shown
in Table 2. In addition, Figure 3 shows the distribution of PCIR
for the patients grouped by TCS (≤ and >3 days) or by TSI group
(classes I-III and IV-V). Comparison of the groups indicated that
there were statistically significant differences in PICR values in
both cases. Patients in the TCS>3d group had significantly higher
PICR compared to the TCS≤3d group (p=0.009) and patients in
PSI class IV-V had higher PICR values compared to those in PSI
classes I-III (p=0.042).
3.4 Predictive value of PICR scores
Based on the statistically significant differences found, ROC
curves were constructed in order to analyze the ability of PICR
scores to predict CAP patient outcomes or severity. As shown in
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Supplementary Fig. 1 Distribution of cytokine values in plasma as shown in Table 1. Box plots depict the 25-75% interquartile range and the
horizontal bar depicts the median. Whiskers represent the 10 and 90 percentiles. Cytokine data from all 40 patients was included.
Figure 4, ROC curves analyzing the ability of PICR to discriminate
between those patients with a TCS≤3d vs. >3d showed area un-
der the curve (AUC) values of 0.893 (p=0.011), consistent with
a very good level of accuracy. The cut-point optimizing specificity
and sensitivity (Youden’s Index) based on this graph is a PICR of
0.96, which would give a sensitivity of 85.7% and a specificity of
87.5%. PICR values were less accurate, however, at discriminat-
ing patients with non-severe vs. severe CAP, as defined by PSI
class (AUC: 0.786; p=0.064).
4 Discussion
Results from this study indicate that, similarly to patients severe
CAP, patients with a TCS>3 days have higher median plasma lev-
els of several pro-inflammatory (IL-6, IL-8) and anti-inflammatory
(IL-10) cytokines compared to those with shorter TCS. Moreover,
our exploratory results suggest that it may be possible to analyze
and integrate cytokine response "patterns" in CAP patients based
on sputum and plasma cytokine levels assayed at hospital admis-
sion. These "patterns" or "scores" (i.e., PICR) may potentially be
used as predictive tools for measures of outcomes and disease
severity, identifying patients at risk to have a delayed TCS or a
more severe disease. With one exception (patient 4), all of the
patients in the TCS≤3d group had PICR values less than 1, sug-
gesting a relatively stronger local compared to systemic response.
The only exception was a patient with Haemophilus influenzae
who had strong systemic and local cytokine responses, yet had
a TCS of 2d. On the other hand, five out of the seven patients
with a TCS>3d had PICR values > 1.00, with the two exceptions
being patients with infections by Pseudomonas aeruginosa and
Acinetobacter baumannii.
Thanks to the current multiplex technology, it is now possible to
measure multiple cytokines in the same sample, resulting in the
generation of a substantial amount of data. However, it is not yet
clear what the best approach is to integrate all of the cytokine in-
formation. Even in our small study, it was evident from comparing
the different individual cytokine patterns that considerable vari-
ability existed in the cytokine responses of the different patients.
Our results suggest, indeed, that analysis of the relationship be-
tween the local and systemic cytokine responses may have some
value in predicting CAP disease severity and outcomes and that
it might help to make predictions and guide potential therapeu-
tic anti-inflammatory and/or immuno-modulatory interventions
even upon admission. Much of the evidence linking the dele-
terious effects of an over-abundant inflammatory response with
the severity of CAP has been based on circulating, and thus sys-
temic, cytokine levels5–8. However, local inflammatory responses
have been less often studied and assumed to be reflected in the
systemic cytokine levels. In a previous study19, as well as the
present study, the distribution of the levels of the different pro-
inflammatory cytokines in plasma supports a more pronounced
systemic inflammatory response in patients with severe CAP or
with a TCS>3d. However, cytokine responses in the sputum did
not follow the same trend as in plasma, suggesting that these two
compartments (lung vs. systemic) do not necessarily mirror each
other.
Our model to integrate the local and systemic inflammatory phe-
notypes in CAP patients was based on the ranked levels of eight
pro-inflammatory cytokines/chemokines. When analyzing the
data, it was clear that not all cytokines in the same patient fol-
lowed the same trends nor that all patients had the same cytokine
patterns. Given the different etiologies and underlying factors in
the different CAP patients, this was not entirely surprising. In-
deed, there were differences of inflammatory phenotypes when
comparing patients with CAP due to different etiological agents,
suggesting that the inflammatory pattern might be influenced by
the etiologic agent, in agreement with previous reports24. The
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Supplementary Fig. 2 Distribution of cytokine values in sputum as shown in Table 1. Box plots depict the 25-75% interquartile range and the
horizontal bar depicts the median. Whiskers represent the 10 and 90 percentiles. Cytokine data from all 15 patients with sputum samples was
included.
Fig. 3 Distribution of PICR scores in patients grouped by TCS (≤3d or >3d) or by PSI risk class (I-III and IV-V). PICR scores were calculated by
dividing pro-inflammatory cytokine scores for plasma by those in sputum as indicated in Materials and Methods. Box plots depict the 25-75%
interquartile range and the horizontal bar depicts the median. Groups were compared using the unpaired t-test. *p < 0.05; **p < 0.01
effect of the etiologic agent in our model remains to be further
investigated. Moreover, while the pro-inflammatory cytokine re-
sponse was the initial focus of our model for this study, the in-
volvement of anti-inflammatory cytokine responses needs also to
be considered.
Clearly, the main limitation of this study is the sample size. Due
to the limited size in this study, our exploratory model needs to
be tested and validated against a more substantial number of pa-
tients. In this study, we only evaluated eight pro-inflammatory
cytokines. Since other cytokines may play an important role in
defining inflammatory phenotypes, including anti-inflammatory
cytokines, future studies should explore additional pro- and anti-
inflammatory cytokines. Additional limitations that may have
had affected the measurements include the fact that our model
is based on a mathematical analysis of cytokine concentrations.
However, given the potential interrelationships among the differ-
ent cytokines, their effect in vivo is much more difficult, if not
impossible, to measure with the current knowledge. Regarding
the patients, pre-hospital admission of steroids and/or antibiotics
may have influenced their responses and will have to be docu-
mented for future studies. Moreover, pre-existing comorbidities,
some of which may induce enhanced systemic inflammation, may
have also the potential to influence cytokine response patterns.
Thus it will be important to characterize how these variables
may affect systemic and local cytokine responses and thus disease
severity and patient outcomes.
A main strength of this study is the fact that both local and sys-
temic cytokine responses were measured at the time of the pa-
tient’s admission, allowing the comparison of the two and their
correlation with measures of disease severity and clinical out-
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Fig. 4 ROC curves comparing the accuracy of PICR values to separate patients by TCS (≤3d or >3d) or PSI (I-III and IV-V) group. AUC values are
indicated in the graphs.
comes. While still preliminary, our results suggest the feasibility
to use cytokine data at hospital admission to help identify those
patients at higher risk. After further validation, such an approach
may facilitate a better understanding of the relationship between
local and systemic inflammatory responses and a more individ-
ualized therapeutic approach to modulate the inflammatory re-
sponse in hospitalized patients with CAP.
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